Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $68.00 by Analysts at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price lowered by Chardan Capital from $91.00 to $68.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. NTLA has been the subject of a number of other reports. Barclays reduced their target price on shares of […]

Mar 3, 2025 - 09:19

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price lowered by Chardan Capital from $91.00 to $68.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. NTLA has been the subject of a number of other reports. Barclays reduced their target price on shares of […]